Last reviewed · How we verify

Mepivacaine Injection

Nova Scotia Health Authority · FDA-approved active Small molecule

Mepivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses.

Mepivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses. Used for Local anesthesia for infiltration, nerve block, and epidural anesthesia, Dental anesthesia.

At a glance

Generic nameMepivacaine Injection
Also known asMEPIVACAINA CLORIDRATO, Prilocaine
SponsorNova Scotia Health Authority
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Mepivacaine reversibly inhibits sodium influx into nerve fibers by binding to sodium channels from the intracellular side, thereby stabilizing the neuronal membrane and raising the threshold for electrical excitability. This action prevents depolarization and conduction of action potentials in sensory and motor nerves, producing localized anesthesia. The drug is an amide-type local anesthetic with intermediate duration of action.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: